Mon, Dec 29, 2014, 1:45 AM EST - U.S. Markets open in 7 hrs 45 mins

Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies, Inc. Message Board

tables777 60 posts  |  Last Activity: Dec 24, 2014 1:10 PM Member since: Oct 27, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I wish you all a wonderful holiday and a new year filled with health, happiness and success. And while we can disagree about many things, let's all agree to make the new year as wonderful as it can be for ourselves, our loved ones and the world around us.

  • Reply to

    New to this company

    by tables777 Dec 18, 2014 3:28 PM
    tables777 tables777 Dec 19, 2014 9:42 AM Flag

    kennbuck: the pps has languished due to the fact that technology was not sanctioned by CMS. That was reversed in 2013. Since then, the company has hired the person who brought Dermagraft to market. Think about it, someone with that kind of reputation and experience would not have signed on without being sure the product works, which it does. Anyway, I think ALQA and NUOT would make a nice fit.

  • Reply to

    New to this company

    by tables777 Dec 18, 2014 3:28 PM
    tables777 tables777 Dec 18, 2014 11:50 PM Flag

    cb: I have been interested in NUOT for a while and someone recently mentioned ALQA and when I read through their recent presentation, it seemed like a natural fit. Aurix has FDA approval and has recently received CMS authorization pending what is called CED registry requirements, which involves recruiting patients for protocols to further demonstrate efficacy, which it assuredly will. In the meantime, each patient enrollee represents a sale. It is on the cusp of becoming a vitally important product in the wound care space and they hired the person who put Shire on the map in this space. So it seems like a good complimentary fit here. What do you think?

  • Reply to

    Message to koko

    by tables777 Dec 18, 2014 12:30 AM
    tables777 tables777 Dec 18, 2014 5:41 PM Flag

    ch3: We all want the same thing. Let's lay off the ridiculous personal attacks. If you disagree with koko, that's ok. Tell us why and let's have a genuine conversation.

    Sentiment: Strong Buy

  • Reply to

    Message to koko

    by tables777 Dec 18, 2014 12:30 AM
    tables777 tables777 Dec 18, 2014 3:30 PM Flag

    Matt: Good to hear from you. ALQA looks quite interesting. But do you think they have the resources to make a serious bid for the company?

  • tables777 by tables777 Dec 18, 2014 3:28 PM Flag

    What do people on this board think about a potential acquisition of NUOT? It seems to fit right in with what the company is trying to achieve. And it will become increasingly clear that this company's product is both clinically and cost effective. Serious replies please.

  • Reply to

    Message to koko

    by tables777 Dec 18, 2014 12:30 AM
    tables777 tables777 Dec 18, 2014 1:35 PM Flag

    If by financial engineering you mean organizing the company to ramp up sales, I would agree. The bottom line is that the product works and is cost effective and the market is significant. Do we need to speculate about conspiracies and lying? There is no need for it. It has taken more time than any of us like to position the company to ramp up sales. You're frustrated. I'm frustrated. Let's just leave it there without maligning anyone's integrity.

    Sentiment: Strong Buy

  • Reply to

    Message to koko

    by tables777 Dec 18, 2014 12:30 AM
    tables777 tables777 Dec 18, 2014 11:15 AM Flag

    Oh, and another thing koko, I stand by my prediction that someone, probably a company like Arthrex or Shire, will buy the company out for between $1.50 and $2 a share, or about $600-$800 million. Tozer will stay on in the new company and do again what he already did at Shire. I'll stand by that.

    Sentiment: Strong Buy

  • Reply to

    Message to koko

    by tables777 Dec 18, 2014 12:30 AM
    tables777 tables777 Dec 18, 2014 11:05 AM Flag

    koko: Yes, I wrote to management and was assured that all protocols are recruiting. The CMS page that states that one of the protocols is not yet recruiting was in error. Koko, be careful. Don't lose your cool. And let's tone down the strident nonsense. It doesn't suit you. I appreciated your correction. Just accept that and let's move on. I'm glad to see you have changed your mind from strong sell back to hold.

    Sentiment: Strong Buy

  • tables777 by tables777 Dec 18, 2014 12:30 AM Flag

    Well, I appreciate your correction on the numbers I posted but then retracted. As JN has noted, the CED sales should generate a few million in sales alone and then when you factor in VA and private hospital sales, he states that the Aurix sales could see $5 million in 2015. I think that may be conservative as increased product awareness about its clinical and cost effectiveness may create a tipping point this coming year. I think Aurix will become the go to product in the three wound care markets that it has approval for. While I thank you for your corrections to my silly numbers, there is no need for the ad hominem comments. Let's leave that for the others on this board.

    Sentiment: Strong Buy

  • Reply to

    Some thoughts about the upcoming year

    by tables777 Dec 17, 2014 10:53 PM
    tables777 tables777 Dec 18, 2014 12:11 AM Flag

    koko: it was almost midnight when I made that off the cuff calculation. Thanks for correcting the fact there will be multiple treatments. But I don't think that the 450 figure covers all of the treatments but reflects the reimbursement rate per treatment. So it would be 450 X 6 or however number of treatments. But there's no need for ad hominem attacks. Let's leave that for the others on this board. But I assume that the company will receive about 50% of each treatment. Do you assume otherwise?

  • Reply to

    CED requirements

    by tables777 Dec 16, 2014 11:16 AM
    tables777 tables777 Dec 16, 2014 1:08 PM Flag

    Remember that the competitors' products lose their price advantage come Jan. 1. As the year wears on, it will become increasingly clear to physicians and hospital administrators that the product is both clinically and cost effective. I am relying on Tozer to get this right in terms of assembling his team and developing a viable strategy. I have seen nothing to dissuade me otherwise.

    Sentiment: Strong Buy

  • tables777 by tables777 Dec 16, 2014 11:16 AM Flag

    I suspect that over the coming year, enrollment in all the protocols will be filled and the data will be gathered and analyzed and CMS will be satisfied that the product is clinically and cost effective and will end CED requirements. Meanwhile, these are all sales.

    Sentiment: Strong Buy

  • Reply to

    Shareholder Christmas Gift

    by jlwbigd Dec 8, 2014 3:15 PM
    tables777 tables777 Dec 8, 2014 5:32 PM Flag

    jlw: I understand the frustration. But good things are on the way. Patients are being enrolled in all 4 trials. There is more enthusiasm about the product shared by more people. Honestly, I am surprised that a company like Shire has not offered to buy the company. With the product's clinical and cost effectiveness, it will look even more attractive going forward. So I am still hopeful the company gets bought out. It will make increasing sense for everyone to consider this. So this may not lift the share price tomorrow, I think we will be in for some interesting times in 2015. The product is just too darn good and the market opportunity is just too darn great and the assembled management and sales team is just too darn experienced for this not to become very interesting.

    Sentiment: Strong Buy

  • Reply to

    ABOVE $.31--$.32 TODAY OR MONDAY

    by ch3howard Dec 5, 2014 3:24 PM
    tables777 tables777 Dec 7, 2014 4:59 PM Flag

    Just put him on ignore.

  • This is really worth repeating. This alone does not mean sales. But it does mean they are doing everything they can to make sure the sales will happen.

    "This award underscores the passion we have for developing tools to support healthcare providers and help them understand the value of the Aurix Systemâ„¢ and its compelling clinical and economic value. For Nuo Therapeutics and our marketing partner BLDG, winning a MarCom Award is a fitting acknowledgment of the quality of the effort we have committed to transform the Company and Product to our market space."

    Sentiment: Strong Buy

  • Reply to

    Message to koko and others

    by tables777 Dec 3, 2014 6:06 PM
    tables777 tables777 Dec 4, 2014 2:01 PM Flag

    thanks koko. I understand your frustration. By the way, I now understand that all four trials are enrolling patients. And I think the unnamed partner left the table for other reasons that had nothing to do with what was happening with the company.

    Sentiment: Strong Buy

  • Reply to

    SELL! BEFORE ITS TOO LATE

    by matthewpitt17 Dec 4, 2014 9:37 AM
    tables777 tables777 Dec 4, 2014 10:54 AM Flag

    Hello Matt: Nice to see you back.

  • Reply to

    Message to koko and others

    by tables777 Dec 3, 2014 6:06 PM
    tables777 tables777 Dec 3, 2014 11:24 PM Flag

    I don't think Jason is distancing himself from the company. He has recently stated that the company will shine next year. I have contacted management about one of the protocols not enrolling yet. Let's see what they say. In the meantime, we all want the same thing. And I think the company is closer to achieving that now than in any time in its history.

    Sentiment: Strong Buy

  • Reply to

    Message to koko and others

    by tables777 Dec 3, 2014 6:06 PM
    tables777 tables777 Dec 3, 2014 6:31 PM Flag

    I have not checked the CMS page but I'll take your word for it. You are pulling the hook too quickly when it comes to the sales force and CMS. You underestimate how difficult it was to clear away all of the bureaucratic and administrative snags. But be that as it may. I hear your frustration. I would be too if I were invested for 8 years. But the CMS decision meant a restart for the company. I think there is another possibility. I believe the company could get bought by Arthrex or by a company like Shire. In fact, I would be surprised if there has not been some discussion of this already. The combined revenue potential for Angel and Aurix justifies a purchase, say, of $2 a share or less than $1 billion. I think a company like Shire and its sales force and Dean's leadership could ramp up sales significantly very quickly. What do you think?

    Sentiment: Strong Buy

SIGA
1.47+0.04(+2.80%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.